Navigation Links
Cytos Biotechnology Presents Additional Results From Phase 2a Study of CYT003 for the Treatment of Allergic Asthma
Date:9/8/2013

o steps from 100% to 50% to 0%. Clinical endpoints included asthma control determined by a validated questionnaire (ACQ), lung function objectively assessed by spirometry (FEV1), day and night-time asthma symptoms and use of relief medication. In addition inflammatory markers (exhaled nitric oxide and eosinophils in the peripheral blood) were evaluated. The study met all clinical endpoints. In patients treated with CYT003 their asthma control improved despite ICS withdrawal. In patients on placebo, the withdrawal of ICS, as expected, led to a worsening of the disease with a statistically significant and clinically important difference between treatment groups. Treatment with CYT003 was safe and generally well tolerated.

About CYT003

Cytos' lead candidate CYT003 is a first-in-class immune modulator in clinical development as a potential new treatment for allergic asthma. CYT003 is currently being evaluated in a global, randomized and placebo-controlled Phase 2b clinical trial as an add-on therapy in 360 patients with moderate to severe allergic asthma not sufficiently controlled on standard controller therapy. The study was initiated in Q4 2012 and top-line results are expected in H1 2014.

Cytos has completed a Phase 2a study demonstrating CYT003 maintains asthma control and lung function, despite standard inhaled corticosteroid withdrawal. Its attractive safety profile is further supported by a database of over 450 patients treated with CYT003 in previous studies.

CYT003 acts via a novel mechanism of action to selectively suppress the body's immune response to allergens, which is considered a predominant risk factor for asthma.

About allergic asthma

Asthma is one of the most common chronic diseases, with an estimated 300 million individuals affected worldwide. Its prevalence is increasing, especially among children, with an expected 400 million patients by 2025. Allergic asthma is the most common type of asthma with 75%-85%
'/>"/>

SOURCE Cytos Biotechnology Ltd
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology news :

1. How plants sense gravity -- a new look at the roles of genetics and the cytoskeleton
2. Frontiers launches new open-access journal in Bioengineering and Biotechnology
3. AAPS announces 2013 National Biotechnology Conference award winners
4. 2013 AAPS National Biotechnology Conference returns to San Diego
5. Governor Corbett Presented 2013 Biotechnology Industry Organization Governor of the Year Award
6. Karl Deisseroth, Gero Miesenböck and Edward Boyden win Brandeis Gabbay Award in Biotechnology
7. Top 10 ways biotechnology could improve our everyday life
8. New Market Forecasts Available for Critical Global Biotechnology Testing and Screening Markets: Molecular Diagnostics, Hematology, Clinical Chemistry and Nucleic Acid Testing
9. Wiley signs collaboration agreement with the Asian Federation of Biotechnology
10. UMN scientists get federal grant for biotechnology development to purify fracking water
11. Biomass characterization technology research highlighted in Industrial Biotechnology journal
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... and POINT ROBERTS, Washington , ... source covering leading sectors including technology and tech stocks, releases ... marketplace featuring master pickpocket and security consultant Apollo Robbins ... stolen and talks about the Wocket™ biometric smart wallet, a ...
(Date:1/22/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/wxdglm/global_wearable ... "Global Wearable Technologies Market and Applications, Opportunities, Industry ... Forecast 2014-2020" report to their offering. ... that can be worn on the user,s body ...
(Date:12/24/2014)... YORK , Dec. 23, 2014  Since its launch in December ... people to eliminate the pain of trying to remember their ... own biometrics fused to their smartphones. To assist people who ... , the company that created 1U and focuses on redefining ...
Breaking Biology News(10 mins):Apollo Robbins Talks about the Illusion of Personal Safety and How Easily Your Wallet is Stolen; If a Wocket Wallet is Stolen the Thief Can't do Anything With it! 2Apollo Robbins Talks about the Illusion of Personal Safety and How Easily Your Wallet is Stolen; If a Wocket Wallet is Stolen the Thief Can't do Anything With it! 3Global Wearable Technologies Market and Applications, Opportunities, Industry Analysis, Segmentation, Size, Growth, Share, Overview, Trends and Forecast 2014-2020 21U Offers Best Solution to the Username / Password Dilemma: For FREE! 21U Offers Best Solution to the Username / Password Dilemma: For FREE! 3
... New research offers tantalizing clues as to why some ... kill themselves. The research is published in the ... Psychological Association (APA). , Neuroscientists at the University of ... doses of fluoxetine hydrochloride, which is sold in the ...
... remarkable fossils found in New Zealand will prompt a major rewrite ... "land of birds" was once home to mammals as well. , ... leg - belonged to a unique, mouse-sized land animal unlike any ... fossil bed, in the Central Otago region of South Island. ...
... during cell division, first described in the late 1800s ... in biology classes, has long fascinated biologists. However, ... division, the "chromosome-spindle" connection, which is critical for the ... elusive. , Researchers at the University of ...
Cached Biology News:Adolescent but not adult hamsters are more aggressive on low dose of fluoxetine 2Tiny bones rewrite textbooks 2Two central mysteries in genome inheritance solved at UCSD 2Two central mysteries in genome inheritance solved at UCSD 3
(Date:2/27/2015)... Brighton, Illinois (PRWEB) February 27, 2015 ... Matt Sims, General Manager of State Line Farms, received ... Award recognizes a producer, under the age of 35, ... , "It is an honor to win the Tomorrow's ... to discovering who won the Top Producer Award and ...
(Date:2/26/2015)... -- On behalf of biotech client GenScript USA, ... & Spitzer, P.A. (Wilentz) secured a significant jury verdict ... excess of $10 million. The jury determined that Genewiz ... it improperly hired one or more of GenScript,s employees.  ... notwithstanding the verdict, a new trial, and remittitur. ...
(Date:2/26/2015)... 26, 2015 Protiviti ( www.protiviti.com ), a ... the Governance Portal , designed to increase the ... (GRC) tasks across multiple business units and projects. The ... customers better align their controls with the COSO ( ... requirements. In response to client feedback, Protiviti has also ...
(Date:2/26/2015)... VIEW, Calif. , Feb. 26, 2015 The ... navigate this ever-changing arena, Frost & Sullivan will host its ... & Sullivan Executive MindXchange , March 8 to 10, at ... San Diego, Calif. This event is ... connected healthcare leaders to discuss industry disruptions and how to ...
Breaking Biology Technology:Matt Sims Receives the 2015 Tomorrow’s Top Producer Horizon Award 2Wilentz Client GenScript Awarded $10 Million in Trade Secrets Case Against Genewiz 2Wilentz Client GenScript Awarded $10 Million in Trade Secrets Case Against Genewiz 3Protiviti Governance Portal Helps Companies Drive Governance, Risk and Compliance Productivity Across Multiple Business Units 2Protiviti Governance Portal Helps Companies Drive Governance, Risk and Compliance Productivity Across Multiple Business Units 3Embrace the Future of Medical Technologies with Frost & Sullivan 2Embrace the Future of Medical Technologies with Frost & Sullivan 3
... from $31.0 million in Q1,08 , - Home Market: $14.4 ... Gross Margin: 21%, up from 13% in Q1,08 , - ... 8 NxStage Medical, Inc. (Nasdaq: NXTM ), ... revenue for the first quarter of 2009 of $33.7 million, ...
... DIEGO, May 7 Cadence Pharmaceuticals, Inc. (Nasdaq: ... on in-licensing, developing and commercializing proprietary product candidates ... reported financial results for the first quarter ended ... development program for Acetavance(TM), our proprietary formulation of ...
... May 7 Encorium Group, Inc. ... contract research organization (CRO) that provides design, development, ... registries to many of the world,s leading pharmaceutical ... Ph.D. has been appointed Head Consultant of Encorium,s ...
Cached Biology Technology:NxStage Reports First Quarter 2009 Financial Results 2NxStage Reports First Quarter 2009 Financial Results 3NxStage Reports First Quarter 2009 Financial Results 4NxStage Reports First Quarter 2009 Financial Results 5NxStage Reports First Quarter 2009 Financial Results 6NxStage Reports First Quarter 2009 Financial Results 7NxStage Reports First Quarter 2009 Financial Results 8NxStage Reports First Quarter 2009 Financial Results 9NxStage Reports First Quarter 2009 Financial Results 10NxStage Reports First Quarter 2009 Financial Results 11Cadence Pharmaceuticals Reports First Quarter 2009 Financial Results 2Cadence Pharmaceuticals Reports First Quarter 2009 Financial Results 3Cadence Pharmaceuticals Reports First Quarter 2009 Financial Results 4Cadence Pharmaceuticals Reports First Quarter 2009 Financial Results 5Cadence Pharmaceuticals Reports First Quarter 2009 Financial Results 6Cadence Pharmaceuticals Reports First Quarter 2009 Financial Results 7Professor Hanna Nohynek Joins Encorium as Head Consultant of its Clinical Vaccine Research Team 2Professor Hanna Nohynek Joins Encorium as Head Consultant of its Clinical Vaccine Research Team 3Professor Hanna Nohynek Joins Encorium as Head Consultant of its Clinical Vaccine Research Team 4